EUCTR2014-005126-35-DE进行中（未招募）1 期
A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer - DESIREE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Locally advanced or metastatic stage of disease not amenable to curative treatment by surgery or radiotherapy alone.
- •- No indication for chemotherapy (e.g. symptomatic visceral metastasis)
- •-Histological confirmed hormone receptor-positive (HR+), HER2-negative carcinoma of the breast.
- •- Postmenopausal women
- •- Disease progression following prior therapy with non steroidal aromatase inhibitors (NSAI), defined as:
- •a. Recurrence while on, or following completion of an adjuvant treatment with Letrozole or Anastrozole, or
- •b. Progression while on or following completion of Letrozole or Anastrozole treatment for ABC/MBC.
- •Note: Non-steroidal aromatase inhibitors (i.e. Letrozole or Anastrozole) do not have to be the last treatment prior to enrollment. Other prior anticancer therapy, e.g. Tamoxifen, Fulvestrant, Exemestane, is also allowed. Patients must have
- •recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to enrollment.
- •- At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation field or there must be pathologic proof of newly progressive disease.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 156
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 156
排除标准
- •- Concurrent immunotherapy or hormonal therapy (contraceptive and/or replacement therapy). Bisphosphonates or denosumab may be continued or started before randomization.
- •- Life expectancy of less than 3 months.
- •- Parenchymal brain metastases, unless adequately controlled by surgery and/or radiotherapy.
- •-Any ongoing toxicity from prior anti-cancer therapy that is grade 3-4 and/or that is progressing in severity, except alopecia or anemia controlled by growth factors.
- •-Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease, angina pectoris requiring anti-anginal medication, previous history of myocardial infarction = 6months, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension (i.e. BP >150/100 mmHg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
- •- Currently active infection.
- •-History of other malignancies within the last 5 years which significantly affect the diagnosis, assessment or prognosis of metastatic breast cancer.
- •-Malabsorption syndrome or insufficient gastrointestinal function, preexisting diagnosis of ulcerative colitis.
- •-Concurrent treatment with other experimental drugs; participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
- •-Insufficiently controlled diabetes, known HIV infection or chronic hepatitis B or C and seriously impaired liver function (Child-Pugh, class A, B or C).
研究者
相似试验
已完成
不适用
A multi-center, randomized, double-blind, phase III clinical trial to evaluate the efficacy and safety of Nebivolol/Rosuvastatin combination treatment in patients with concomitant Hypertension and HyperlipidemiaDiseases of the circulatory systemKCT0002148Elyson Pharmaceutical276
进行中（未招募）
1 期
A multi-center, randomized, double-blind, phase II trial with intraindividual comparison to assess superiority of Soventol HydroCortisonACETAT 1 % Cremogel versus vehicle on lesional skin in patients with mild atopic eczema, seborrheic eczema or stasis dermatitis and to assess safety of Soventol HydroCortisonACETAT 1 % CremogelEUCTR2017-000984-34-DEMedice Arzneimittel Pütter GmbH & Co KG50
进行中（未招募）
不适用
Comparison of defined skin parameters in two comparable lesional skin areas after topical treatment with Soventol HydroCort 1% cream or vehiclemanifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitisMedDRA version: 14.1Level: PTClassification code 10041955Term: Stasis dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 14.1Level: LLTClassification code 10062813Term: Seborrheic eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 14.1Level: LLTClassification code 10003641Term: Atopic eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2013-000715-25-DEMEDICE Arzneimittel Pütter GmbH & Co.KG
进行中（未招募）
不适用
Comparison of defined skin parameters in two comparable lesional skinareas after topical treatment with Soventol HydroCort 0.5 % Cremogel or Placebomanifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitisEUCTR2011-001175-38-DEMEDICE Arzneimittel Pütter GmbH & CO.KG
进行中（未招募）
不适用
A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn’s disease (Ileo-Colitis)ACTIVE CROHN'S DISEASEMedDRA version: 14.1Level: LLTClassification code 10021315Term: Ileitis terminalSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-002640-27-ITGIULIANI